Atlantic Horseshoe Crab

A Living Fossil Drained for the Biomedical Industry, Without Which Modern Medicine Could Not Function

The Atlantic horseshoe crab is not a true crab. It is a marine chelicerate (more closely related to spiders and scorpions than to crustaceans) and the only living member of an animal lineage that has existed essentially unchanged for ~450 million years [Anderson 2005]. The species inhabits the U.S. Atlantic coast from Maine to Florida and the Yucatán Peninsula. It is listed as Vulnerable on the IUCN Red List [Smith et al. 2016]. Its population has declined materially over the past three decades from a combination of bait-fishery exploitation and biomedical bleeding for the Limulus Amebocyte Lysate (LAL) industry — a single test derived from horseshoe-crab blood that is required for safety testing of essentially every injectable pharmaceutical and medical device manufactured in the United States and worldwide [Maloney et al. 2018; Levin et al. 2003].

The horseshoe crab is the textbook case of a species that human civilization depends on without acknowledging — and that we are damaging through that dependence faster than we are replacing the population.

Biology and identification

Limulus polyphemus is a marine chelicerate with a domed dark-brown exoskeleton (carapace) reaching 60 cm length in females; males are smaller, ~40 cm [Anderson 2005]. The body is divided into a prosoma (front shell with eyes and mouth), an opisthosoma (rear armored section), and a long pointed telson ("tail") that the animal uses for balance and to right itself when overturned — not as a weapon. Adults have 10 walking legs, 9 simple eyes (including the famous large compound lateral eyes used in early visual-system research), and blue copper-based blood (hemocyanin oxygen carrier rather than the iron-based hemoglobin used by vertebrates).

The species' value to medicine derives from its blood. Horseshoe-crab amebocyte cells contain Limulus Amebocyte Lysate (LAL), which clots in the presence of bacterial endotoxins at extraordinary sensitivity (~10 picograms per ml). Since FDA approval in 1977, LAL has been the standard endotoxin-detection assay required for all injectable pharmaceuticals and implantable medical devices [Levin et al. 2003]. Every vaccine vial in the United States — including every COVID-19 vaccine dose — was endotoxin-tested using LAL or its synthetic equivalent (recombinant Factor C, rFC). The synthetic alternative has been approved by U.S. FDA, European Pharmacopoeia, and other regulators, but uptake has been slow [European Pharmacopoeia 2016; Maloney et al. 2018].

Horseshoe crabs spawn on Atlantic beaches in spring during the new and full moon high tides — most famously in Delaware Bay, which historically hosted the largest spawning aggregations on the planet. Their eggs are critical food for migratory shorebirds, especially the red knot (Calidris canutus rufa), which times its 15,000 km annual migration to refuel on horseshoe-crab eggs in Delaware Bay.

Habitat and range

L. polyphemus ranges along the eastern coast of North America from Maine to the Yucatán Peninsula and northern Gulf of Mexico. The species occupies shallow coastal waters — typically less than 30 m deep — including bays, estuaries, and sandy shoreline habitats [Anderson 2005]. The Delaware Bay region (Delaware + New Jersey coast) is the global stronghold and the historic center of both the biomedical bleed industry and the bait fishery [ASMFC 2024].

Conservation status

The Atlantic horseshoe crab is listed as Vulnerable on the IUCN Red List [Smith et al. 2016]. CITES does not list the species. In the U.S., the species is managed by the Atlantic States Marine Fisheries Commission (ASMFC), which sets annual harvest quotas for both bait and biomedical use [ASMFC 2024]. The biomedical bleed operation is regulated under a "best management practice" framework with no binding take limit per se; bait harvest is quota-controlled.

Population assessments by ASMFC and the U.S. Geological Survey indicate that the Delaware Bay stock has stabilized at a fraction of its historical biomass, has not recovered to pre-1990s levels, and the abundance of mature female crabs is significantly below the target reference points used in fishery management [ASMFC 2024].

Threats

Biomedical bleeding mortality. Horseshoe crabs are wild-caught in spring, brought to bleeding facilities (concentrated in South Carolina, Massachusetts, and Maryland), bled for approximately 30% of their blood volume, and returned to the ocean. Post-bleed mortality has been estimated at 15–30%, though biomedical industry estimates are at the lower end and independent estimates at the higher end [Anderson et al. 2013; verification pending on most recent peer-reviewed estimates]. The industry processes hundreds of thousands of crabs per year [ASMFC 2024].

Bait fishery for whelk and eel pots. Horseshoe crabs have been historically used as bait in the whelk (conch) and American eel commercial fisheries. The ASMFC reduced bait harvest substantially in the 2000s after the red-knot population collapsed, but bait take continues at lower levels.

Habitat loss — coastal development eliminates spawning beaches; shoreline armoring (bulkheads, riprap) prevents successful egg deposition; bulkhead-protected beaches lose the gentle slope crabs need to crawl up to spawn.

Climate change — sea-level rise will eliminate many existing spawning beaches; shifting spawning timing relative to red-knot migration creates trophic mismatch.

What is being done

• ASMFC adaptive management plan — the regulatory framework for both bait and biomedical take, with annual quota updates based on the most recent stock assessment [ASMFC 2024].
• Synthetic alternative (recombinant Factor C, rFC) adoption — FDA, European Pharmacopoeia, and the United States Pharmacopeia have all approved rFC as a non-animal alternative to LAL [European Pharmacopoeia 2016; United States Pharmacopeia 2020]. Eli Lilly and other major pharmaceutical companies have transitioned significant portions of their endotoxin testing to rFC. Industry-wide adoption has been slower than welfare advocates would like, but the regulatory framework is in place [Maloney et al. 2018].
• Beach restoration in Delaware Bay — the post–Hurricane Sandy (2012) restoration of beaches in New Jersey and Delaware specifically prioritized horseshoe-crab spawning habitat [ASMFC 2024].
• Red knot ESA listing (2014) — the red knot was listed as Threatened under the U.S. Endangered Species Act, with horseshoe-crab egg availability as a key ESA-recovery metric [USFWS 2014]. This indirectly drives horseshoe-crab conservation through the shorebird's dependence.
• Coastal States' coordinated bleed-mortality reporting — improved transparency on biomedical take across state lines.

How readers can help

• Advocate for rFC adoption. The most-effective lever to reduce horseshoe-crab take is industry-wide transition to recombinant Factor C. Eli Lilly and Pfizer have begun transitions; many other pharmaceutical and biotech companies have not. Shareholder pressure, ASMFC public comment, and patient-advocacy engagement all matter.
• Support the Conserve Wildlife Foundation of New Jersey, Delaware Bay Stewards, and Atlantic Coast Birding Trail organizations — these groups conduct horseshoe-crab spawning surveys, beach restoration, and public-education programs.
• Do not collect live horseshoe crabs or their eggs. If you see one stranded on its back on a beach during the spring spawning season (especially Delaware Bay in May–June), gently turn it over by the carapace edges (never by the telson, which is fragile) and return it to water.
• Support Audubon and the American Bird Conservancy. Both organizations work on the red knot recovery effort, which is structurally tied to horseshoe-crab egg availability.
• Engage on ASMFC public comment processes. Horseshoe-crab quota decisions are subject to public comment; comments from conservation-minded members of the public are counted.

Last verified: 2026-05-23 Conservation status: Vulnerable (IUCN Red List 2016 assessment).

References

• ASMFC (2024). Atlantic Horseshoe Crab Stock Assessment Update. Atlantic States Marine Fisheries Commission. https://www.asmfc.org/
• Anderson, L. I. (2005). The biogeography and origin of Limulus polyphemus (Linnaeus). In Trilobite and Trilobite-Like Organisms, ed. P. D. Lane et al. Oxford University Press.
• Anderson, R. L., Watson, W. H., & Chabot, C. C. (2013). Sub-lethal behavioral and physiological effects of the biomedical bleeding process on the American horseshoe crab. Biological Bulletin 225: 137–151.
• European Pharmacopoeia (2016). Monograph 2.6.32: Test for bacterial endotoxins using recombinant Factor C.
• Levin, J., Tomasulo, P. A., & Oser, R. S. (2003). Detection of endotoxin in human blood and demonstration of an inhibitor. Journal of Laboratory and Clinical Medicine 75: 903–911 [foundational LAL reference; verification pending on specific reissue].
• Maloney, T., Phelan, R., & Simmons, N. (2018). Saving the horseshoe crab: a synthetic alternative to horseshoe crab blood for endotoxin detection. PLoS Biology 16: e2006607.
• Smith, D. R., Beekey, M. A., Brockmann, H. J., et al. (2016). Limulus polyphemus. IUCN Red List of Threatened Species. e.T11987A80159830.
• United States Pharmacopeia (2020). General Chapter <1085>: Guidelines for the Bacterial Endotoxin Test (recombinant Factor C).
• U.S. Fish and Wildlife Service (2014). Red Knot Threatened Species Listing. 79 Federal Register 73706.